1
EXHIBIT 4
A D A C
Laboratories
LETTER TO SHAREHOLDERS
November 14, 2000
Dear Shareholders:
We are pleased to inform you that, on November 12, 2000, ADAC Laboratories
("ADAC") entered into an Agreement and Plan of Merger (the "Merger Agreement")
with Philips Holding USA Inc. ("Philips") and Philips Medical Acquisition
Corporation, Philips' wholly-owned subsidiary, providing for the acquisition of
ADAC. Pursuant to the Merger Agreement, Philips Medical Acquisition Corporation
has commenced a tender offer for all the outstanding shares of ADAC's common
stock at $18.50 per share, net to the sellers in cash (the "Offer").
Following the successful completion of the Offer, Philips Medical
Acquisition Corporation will merge into ADAC (the "Merger"), and all the shares
not purchased in the Offer will be converted into the right to receive $18.50
per share in cash in the Merger without interest. As a result of the Merger,
ADAC will become a wholly-owned subsidiary of Philips.
YOUR BOARD OF DIRECTORS HAS (1) UNANIMOUSLY DETERMINED THAT EACH OF THE
MERGER AGREEMENT, THE OFFER AND THE MERGER IS FAIR TO, AND IN THE BEST INTERESTS
OF, THE SHAREHOLDERS OF ADAC; (2) DULY APPROVED THE MERGER AGREEMENT AND RELATED
AGREEMENTS AND THE TRANSACTIONS CONTEMPLATED THEREBY, INCLUDING THE OFFER AND
THE MERGER; AND (3) UNANIMOUSLY RECOMMENDED THAT THE SHAREHOLDERS OF ADAC ACCEPT
THE OFFER AND TENDER THEIR SHARES PURSUANT TO THE OFFER, AND APPROVE AND ADOPT
THE MERGER AGREEMENT AND THE MERGER.
Enclosed with this letter is a copy of ADAC's Solicitation/Recommendation
Statement on Schedule 14D-9, which describes the reasons for your Board's
recommendation. Also enclosed are the Offer to Purchase by Philips Medical
Acquisition Corporation, together with related materials, including a Letter of
Transmittal to be used for tendering your shares. These materials set forth in
detail the terms and conditions of the tender offer, and provide instructions on
how to tender your shares. I urge you to read the enclosed materials carefully.
Very truly yours,
X. XXXXXX XXXXXX
Chief Executive Officer